Home » FDA Awards Breakthrough Therapy Designation to Merck’s Keytruda
FDA Awards Breakthrough Therapy Designation to Merck’s Keytruda
The FDA has granted breakthrough therapy designation to Merck’s Keytruda, an anti-PD-1 therapy for treating patients with microsatellite instability high metastatic colorectal cancer.
The breakthrough designation is based on Phase 2 data of the drug’s activity in cancers with microsatellite instability, a feature present in cells with certain types of DNA repair defects.
Merck is conducting a Phase 3 study of the drug in a treatment-naïve patient population.
Keytruda (pembrolizumab) previously was granted breakthrough status for advanced melanoma and advanced non-small cell lung cancer.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May